Mylan's chairman Robert Coury made roughly $98 million in 2016, a year in which the company faced criticism for the price of the EpiPen and the stock fell almost 30%, according to company filings.

On top of that, The Wall Street Journal reported, Coury made $66.3 million in other payments, including retirement benefits, bringing the amount he made in 2016 to $164 million.

According to the filings, Coury will continue to receive $1.8 million a year. Coury had originally served as CEO of Mylan from 2002 to 2011. Before June 2016, Coury had served as executive chairman, a role he held since 2012 when Heather Bresch became CEO.

Mylan told the WSJ in a statement:

The generic pharmaceutical company came into the spotlight in August 2016 raising the price of the EpiPen

From May 2016 to May 2017, Mylan's stock is down 12.4%.